Prosecution Insights
Last updated: July 05, 2026
Application No. 18/160,870

VASCULAR PLAQUE EXTRACTION APPARATUS AND METHOD

Final Rejection §103§112
Filed
Jan 27, 2023
Priority
Jan 29, 2022 — CN 202210111238.6
Examiner
O'MALLEY, CONOR AIDAN
Art Unit
2675
Tech Center
2600 — Communications
Assignee
GE Precision Healthcare LLC
OA Round
4 (Final)
68%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
66%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
23 granted / 34 resolved
+5.6% vs TC avg
Minimal -2% lift
Without
With
+-1.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
14 currently pending
Career history
55
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
71.0%
+31.0% vs TC avg
§102
21.0%
-19.0% vs TC avg
§112
3.0%
-37.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 34 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-15 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claims contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventors, at the time the application was filed, had possession of the claimed invention. The amended claims present a variety of instances of new matter such as “background voxels”, “by a predetermined radial distance”, and “creating a perivascular region for radiomics feature extraction”. The specification only discloses the mention of merging “background points” in paragraph 71, and while this would allow for the previously recited, “background features” to be enabled. “Background voxels” is more specific and not covered by the specification. For, “predetermined radial distance”, there is no recitation of any “predetermined radial distance” in the specification or drawings. Further, neither the terms radial nor predetermined appear at all within the specification, as such, how can this term be anything but new matter? There is no recitation of radial or predetermined anywhere within the application. For, “creating a perivascular region for radiomics feature extraction”, firstly perivascular is not recited anywhere within the specification or drawings. Secondly, there are two issues with “perivascular region”, “perivascular region” could mean either “perivascular spaces” or “region around the blood vessel”. Now, the “perivascular spaces” definition would essentially have the claim claiming that this image processing technique is being used to create fluid filled spaces around blood vessels which would be far from the scope of the invention. The second definition is equally problematic, Paragraph 79 of the specification states that, “Due to the dilation operation on the vascular lumen image in the process of extracting the voxel feature map, some pixels considered to be plaques may exceed the range of the vascular lumen, and by taking the intersection of the potential plaque and the vascular lumen image, the misjudgment can be eliminated and plaques outside the vascular lumen can be excluded” which would explicitly exclude creating a perivascular region as areas outside the blood vessels in the CCTA images are excluded to avoid misjudgment. So, the specification would actually teach away from the claim language by noting that the perivascular region is purposefully excluded. As such, for these reasons, these claims recite new matter, and the dependent claims inherit these issues, and are similarly rejected. Response to Amendment The amendments, entered 3/19/2026, have been entered in full, and they have been fully considered. These amendments overcome the current 103 rejection, but they have new matter which means they are subject to a rejection under 112(a). Response to Arguments Applicant’s arguments, see pages 6-8, filed 3/19/2026, with respect to the rejections of claims 1-15 under 35 U.S.C. 103 have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new grounds of rejection is made in view of 35 U.S.C. 112(a). Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CONOR AIDAN O'MALLEY whose telephone number is (571)272-0226. The examiner can normally be reached Monday - Friday 9:00 am. - 5:00 pm. EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Moyer can be reached at 5722729523. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. CONOR AIDAN. O'MALLEY Examiner Art Unit 2675 /CONOR A O'MALLEY/Examiner, Art Unit 2675 /ANDREW M MOYER/Supervisory Patent Examiner, Art Unit 2675
Read full office action

Prosecution Timeline

Show 10 earlier events
Nov 25, 2025
Request for Continued Examination
Dec 08, 2025
Response after Non-Final Action
Dec 19, 2025
Non-Final Rejection mailed — §103, §112
Mar 19, 2026
Response Filed
Apr 09, 2026
Final Rejection mailed — §103, §112
Jun 03, 2026
Interview Requested
Jun 17, 2026
Examiner Interview Summary
Jun 17, 2026
Applicant Interview (Telephonic)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12670564
IMAGE PROCESSING APPARATUS, IMAGE PROCESSING METHOD, AND NON-TRANSITORY COMPUTER-READABLE STORAGE MEDIUM
2y 7m to grant Granted Jun 30, 2026
Patent 12664782
PROCESSING IMAGES FOR EXTRACTING INFORMATION ABOUT KNOWN OBJECTS
3y 6m to grant Granted Jun 23, 2026
Patent 12648067
METHOD FOR CONTROLLING AN AUTOMOTIVE LIGHTING DEVICE
2y 9m to grant Granted Jun 02, 2026
Patent 12632937
INFORMATION PROCESSING DEVICE, AND OPERATION METHOD AND OPERATION PROGRAM THEREOF
3y 5m to grant Granted May 19, 2026
Patent 12608908
SYSTEM AND METHOD FOR DETECTION OF ROAD FEATURES BASED ON ARTIFICIAL SHADOW DATA
3y 0m to grant Granted Apr 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
68%
Grant Probability
66%
With Interview (-1.5%)
2y 10m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 34 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month